Upcoming EventsMore >>
There are currently no events scheduled.
Recent NewsMore >>
12/17/14Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend
THOUSAND OAKS, Calif., Dec. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $0.79 per share dividend for the first quarter of 2015. The dividend will be paid on March 6, 2015, to all stockholders of record as of the close of business on Feb. 12, 2015. This represents a 30 percent increase from that paid in each of the previous four quarters. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from s... 
Printer Friendly Version
12/11/14Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec. 11, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that additional results from AMAGINE-1TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in patients with moderate-to-severe plaque psoriasis will be presented at the Psoriasis: From Gene to Clinic International Congress in London on Saturday, Dec. 13, 2014, at 11:20 a.m. G... 
Printer Friendly Version
12/08/14Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif., Dec. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO™ (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology (ASH) Annual Meeting a... 
Printer Friendly Version
12/08/14New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma
Study is the First to Evaluate Investigational Combination of an Oncolytic Immunotherapy and Anti-PD-1 Therapy THOUSAND OAKS, Calif., Dec. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the initiation of a trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, in combination with an investigational use of Merck's U.S. Food and Drug Administration (FDA) approved, anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with regionally or distantly metast... 
Printer Friendly Version
What's New
Download Documentation ASH Conference Presentation
Download Documentation Jefferies Healthcare Conference Presentation
Download Documentation AHA Conference Presentation
Download Documentation Credit Suisse Healthcare Conference Presentation
Download Documentation Investor Insights Newsletter - Q3 2014
Download Documentation 2014 Business Review – Bradway
Download Documentation Amgen Research & Development – Harper
Download Documentation Kyprolis (carfilzomib) for injection and Blinatumomab - Cagnoni
Download Documentation Commercial Strategy - Hooper
Download Documentation Biosimilars - Foraker
Investor Insights Newsletters
Download Documentation Investor Insights Newsletter - Q3 2014
Download Documentation Investor Insights Newsletter - Q2 2014
Download Documentation Investor Insights Newsletter - Q1 2014
Download Documentation Investor Insights Newsletter - Q4 2013
Download Documentation Investor Insights Newsletter - Q3 2013

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.